Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy

被引：0
|
作者：
Ramdial, J. [1 ]
Chan, K. H. [1 ]
Sanchez Petitto, G. [1 ]
Valdez, B. [1 ]
Andersson, B. S. [1 ]
Nieto, Y. [1 ]
机构：
[1] UT MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / 06期
关键词：
STEM-CELL TRANSPLANTATION; TOTAL-BODY IRRADIATION; DAILY IV-BUSULFAN; VENOOCCLUSIVE DISEASE; FLUDARABINE; CYCLOPHOSPHAMIDE; REGIMEN; GEMCITABINE; MELPHALAN; TOXICITY;
D O I：
10.1038/s41409-023-01964-y
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：635 / 638
页数：4
相关论文
共 50 条
  • [31] Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma
    Nieto, Yago
    Ramdial, Jeremy
    Valdez, Benigno
    Thall, Peter F.
    Bassett, Roland
    Barnett, Melissa
    Srour, Samer
    Hosing, Chitra
    Alousi, Amin
    Qazilbash, Muzaffar
    Popat, Uday
    Gulbis, Alison
    Shigle, Terri Lynn
    Ahmed, Sairah
    Pacheco, Maria Guillermo
    Champlin, Richard
    Shpall, Elizabeth J.
    Andersson, Borje S.
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 975 - 982
  • [32] Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide
    Worth, LL
    Tran, H
    Petropoulos, D
    Culbert, SC
    Mullen, CA
    Roberts, WM
    Przepiorka, D
    Chan, KW
    BONE MARROW TRANSPLANTATION, 1999, 24 (09) : 947 - 952
  • [33] Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide
    LL Worth
    H Tran
    D Petropoulos
    SC Culbert
    CA Mullen
    WM Roberts
    D Przepiorka
    KW Chan
    Bone Marrow Transplantation, 1999, 24 : 947 - 952
  • [34] Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial
    Blanes, Margarita
    de la Rubia, Javier
    Lahuerta, Juan J.
    Gonzalez, Jose D.
    Ribas, Paz
    Solano, Carlos
    Alegre, Adrian
    Sanz, Miguel A.
    LEUKEMIA & LYMPHOMA, 2009, 50 (02) : 216 - 222
  • [35] Caring beyond cure: quality of life after high-dose chemotherapy for patients with relapsed Hodgkin lymphoma
    Borchmann, Peter
    LEUKEMIA & LYMPHOMA, 2010, 51 (11) : 1949 - 1950
  • [36] Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI
    Garming-Legert, K.
    Remberger, M.
    Ringden, O.
    Hassan, M.
    Dahllof, G.
    ORAL DISEASES, 2011, 17 (07) : 670 - 676
  • [37] Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma
    Kuittinen, Taru
    Jantunen, Esa
    Vanninen, Esko
    Mussalo, Hanna
    Nousiainen, Tapio
    Hartikainen, Juha
    CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING, 2010, 30 (03) : 175 - 180
  • [38] The current role of high-dose chemotherapy in oncology
    Engert, A
    Josting, A
    Reiser, M
    Söhngen, D
    Diehl, V
    MEDIZINISCHE KLINIK, 1999, 94 (08) : 431 - 442
  • [39] Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma
    Hyung, Jaewon
    Hong, Jung Yong
    Yoon, Dok Hyun
    Kim, Shin
    Park, Jung Sun
    Park, Chan-sik
    Lee, Sang-wook
    Kim, Jeong Hoon
    Ryu, Jin Sook
    Huh, Jooryung
    Suh, Cheolwon
    ANNALS OF HEMATOLOGY, 2019, 98 (07) : 1657 - 1664
  • [40] High-dose chemotherapy in childhood brain tumours
    Kalifa, C
    Valteau, D
    Pizer, B
    Vassal, G
    Grill, J
    Hartmann, O
    CHILDS NERVOUS SYSTEM, 1999, 15 (10) : 498 - 505
12345